The investigators conducted a multicenter, double-blind, placebo-controlled, active-controlled phase 3a trial (ClinicalTrials.gov ID: NCT05567796) evaluating the efficacy and safety of the combination of semaglutide and cagrilintide in adults without diabetes with a body-mass index (BMI) of greater than or equal to 30 or greater than or equal to 27 with at least one obesity-related complication
Red flags include: No baseline lab work Unwillingness to adjust dosing based on your results Products from unknown or unverifiable sources Peptide weight loss therapy offers an exciting, targeted approach to fat reduction, muscle preservation, and metabolic health
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein involved in actin sequestration, cell migration, and extracellular matrix remodeling
van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH